Nektar Therapeutics Past Earnings Performance

Past criteria checks 0/6

Nektar Therapeutics's earnings have been declining at an average annual rate of -20.1%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been declining at an average rate of 53.8% per year.

Key information

-20.1%

Earnings growth rate

-19.5%

EPS growth rate

Pharmaceuticals Industry Growth	6.0%
Revenue growth rate	-53.8%
Return on equity	-210.8%
Net Margin	-306.3%
Last Earnings Update	31 Dec 2023

Recent past performance updates

Recent updates

There's No Escaping Nektar Therapeutics' (NASDAQ:NKTR) Muted Revenues Despite A 44% Share Price Rise

Feb 15

Nektar Therapeutics' (NASDAQ:NKTR) Business And Shares Still Trailing The Industry

Dec 31

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?

Aug 19

Nektar: Time To Abandon Ship

Jul 17

Nektar promotes internal executive to CFO role

Jul 01

We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully

May 11

After A High-Profile Failure In Melanoma, Nektar Therapeutics' Value Shifts To Its Early-Stage Pipeline

Apr 04

Analysts Just Made A Major Revision To Their Nektar Therapeutics (NASDAQ:NKTR) Revenue Forecasts

Mar 09

Nektar Therapeutics: Beaten Down By 2020

Jan 26

We Think Nektar Therapeutics (NASDAQ:NKTR) Can Easily Afford To Drive Business Growth

Jan 13

Nektar Therapeutics (NASDAQ:NKTR) Analysts Just Trimmed Their Revenue Forecasts By 11%

Dec 09

Nektar Therapeutics (NASDAQ:NKTR) Is In A Strong Position To Grow Its Business

Oct 05

Nektar Therapeutics' Short Covering Surges By 200% In 2 Weeks

Sep 29

Nektar Sends Shot Across Bristol Myers Squibb's Bow With Big Pfizer Collaboration

Sep 23

Revenue & Expenses Breakdown
Beta

How Nektar Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:NKTR Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	90	-276	77	114
30 Sep 23	88	-294	82	119
30 Jun 23	88	-307	83	128
31 Mar 23	89	-415	86	142
31 Dec 22	92	-368	92	218
30 Sep 22	95	-454	103	283
30 Jun 22	96	-525	109	353
31 Mar 22	103	-491	119	412
31 Dec 21	102	-524	123	400
30 Sep 21	100	-495	118	403
30 Jun 21	105	-474	115	400
31 Mar 21	126	-429	110	395
31 Dec 20	153	-444	105	409
30 Sep 20	163	-439	126	395
30 Jun 20	163	-429	123	394
31 Mar 20	137	-460	121	404
31 Dec 19	115	-441	99	435
30 Sep 19	121	-427	95	433
30 Jun 19	119	-424	90	437
31 Mar 19	1,184	657	88	419
31 Dec 18	1,193	681	94	387
30 Sep 18	1,249	746	70	372
30 Jun 18	1,374	903	63	335
31 Mar 18	321	-129	59	307
31 Dec 17	308	-97	52	268
30 Sep 17	250	-105	53	237
30 Jun 17	133	-209	51	224
31 Mar 17	131	-198	46	216
31 Dec 16	165	-154	44	204
30 Sep 16	167	-165	45	198
30 Jun 16	191	-130	44	189
31 Mar 16	181	-134	43	182
31 Dec 15	231	-81	46	180
30 Sep 15	211	-73	45	171
30 Jun 15	284	6	45	162
31 Mar 15	290	26	45	153
31 Dec 14	201	-54	44	145
30 Sep 14	212	-56	41	155
30 Jun 14	140	-143	43	164
31 Mar 14	146	-153	43	180
31 Dec 13	149	-162	43	187
30 Sep 13	139	-167	44	185
30 Jun 13	96	-194	44	175

Quality Earnings: NKTR is currently unprofitable.

Growing Profit Margin: NKTR is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: NKTR is unprofitable, and losses have increased over the past 5 years at a rate of 20.1% per year.

Accelerating Growth: Unable to compare NKTR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NKTR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.8%).

Return on Equity

High ROE: NKTR has a negative Return on Equity (-210.75%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Nektar Therapeutics Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Nektar Therapeutics to Report Q4, 2023 Results on Mar 04, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Nektar Therapeutics to Report Q3, 2023 Results on Nov 07, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Nektar Therapeutics to Report Q2, 2023 Results on Aug 08, 2023

Recent updates

New major risk - Share price stability

Nektar Therapeutics announced that it has received $30 million in funding from TCG Crossover Management, LLC

Consensus EPS estimates fall by 12%

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Nektar Therapeutics Announces Initiation of Phase 2B Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata

Nektar Therapeutics announced that it expects to receive $30 million in funding from TCG Crossover Management, LLC

Nektar Therapeutics to Report Q4, 2023 Results on Mar 04, 2024

There's No Escaping Nektar Therapeutics' (NASDAQ:NKTR) Muted Revenues Despite A 44% Share Price Rise

Price target decreased by 83% to US$0.50

Nektar Therapeutics' (NASDAQ:NKTR) Business And Shares Still Trailing The Industry

Nasdaq States Nektar Therapeutics Eligible for an Additional 180 Calendar Day Period, or Until May 20, 2024, to Regain Compliance with the Minimum Bid Price Requirement

Nasdaq States Nektar Therapeutics Eligible for an Additional 180 Calendar Day Period, or Until May 20, 2024, to Regain Compliance with the Minimum Bid Price Requirement

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Nektar Therapeutics to Report Q3, 2023 Results on Nov 07, 2023

Nektar Therapeutics Presents New Responder Data for Rezpegaldesleukin, A First-In-Class Selective Regulatory T-Cell Therapy

Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate Nktr-255 in Combination with C-Til051 in Advanced Non-Small Cell Lung Cancer

Price target increased by 21% to US$2.88

Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-To-Severe Atopic Dermatitis

Price target increased by 14% to US$2.70

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Share price stability

Nektar Therapeutics Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company

Nektar Therapeutics to Report Q2, 2023 Results on Aug 08, 2023

Price target decreased by 7.3% to US$2.35

New minor risk - Market cap size

Nektar Therapeutics(NasdaqGS:NKTR) dropped from Russell 2000 Index

New minor risk - Market cap size

Nektar Therapeutics Receives Notice from The Nasdaq Global Select Market Due to Non-Compliance with the Minimum Bid Price Rule

Price target increased by 18% to US$3.00

Consensus EPS estimates fall by 63%, revenue upgraded

Price target decreased by 7.8% to US$2.70

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Nektar Therapeutics Reports Impairment of Goodwill for the First Quarter Ended March 31, 2023

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Full year 2022 earnings: EPS exceeds analyst expectations

Price target decreased by 21% to US$3.60

CEO, President & Director recently sold US$59k worth of stock

Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely

Insufficient new directors

CEO, President & Director recently sold US$136k worth of stock

Insider recently sold US$48k worth of stock

Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, A Novel Polymer-Conjugated Human IL-15, Improves Efficacy of CD19-Targeted CAR-T Cell Immunotherapy

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Nektar Therapeutics to Report Q3, 2022 Results on Nov 03, 2022

Nektar Therapeutics (NasdaqGS:NKTR) submitted a non-binding proposal to acquire PureTech Health plc (LSE:PRTC).

Independent Director notifies of intention to sell stock

Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (Eadv) Congress

Insider notifies of intention to sell stock

CEO, President & Director recently sold US$65k worth of stock

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?

Nektar Therapeutics Announces Preclinical Publication of Data for NKTR-255 and Its Observed Improvement of NK Cell Function in Multiple Myeloma

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Nektar Therapeutics Provides Earnings Guidance for the Year 2022

Nektar Therapeutics to Report Q2, 2022 Results on Aug 04, 2022

Nektar: Time To Abandon Ship

Nektar Promotes Jillian B. Thomsen to Senior Vice President

Nektar promotes internal executive to CFO role

Nektar Therapeutics(NasdaqGS:NKTR) dropped from Russell 1000 Dynamic Index

Price target decreased to US$4.83

Nektar Therapeutics Reviews Interim Efficacy and Safety Data from the Ongoing Phase 2 Double Blinded, Placebo-Controlled Study

CEO, President & Director recently sold US$144k worth of stock

We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully

First quarter 2022 earnings: EPS exceeds analyst expectations

Price target decreased to US$5.96

Nektar Therapeutics, Annual General Meeting, Jun 08, 2022

Consensus forecasts updated

John Northcott Step Down as Senior Vice President and Chief Commercial Officer of Nektar Therapeutics

Nektar Therapeutics and Bristol-Myers Squibb Company Announce Update on Clinical Development Program for Bempegaldesleukin (Bempeg) in Combination with Opdivo (Nivolumab)

Revenue & Expenses Breakdown
Beta